Fundamental Data for CELG

CELGENE CO(NSDQ:CELG)

Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

# Employees: 2441

Address: 86 Morris Avenue,Summit,NJ,USA

Phone: 908 673-9000

Fax:

Website: www.celgene.com

Email:

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Sol J. Barer (Chmn.; C.E.O.)

David W. Gryska (C.F.O.)

Robert J. Hugin (C.O.O.; Dir.)

Ernest Mario (Dir.)

Michael D. Casey (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 1/28/2010

Mean EPS (Next Qtr): $0.57

Mean EPS (Year): $1.85

Mean Estimate(Long Term): $24.14

P/E Ratio(Based on EPS estimate): 29.710

Number of Estimates: 11

Shares Performance

Period	CELG	Compare to S&P
YTD	-0.56 %	-17.71 %
4 Weeks	7.68 %	2.22 %
12 Weeks	6.24 %	-1.07 %

Shares Information

Analyst Coverage: Y

Avg Volume: 2985388

Shares Outstanding: 458M

Market Cap: $25.21B

52 Week High: $57.79

52 Week Low: $38.01

P/E Ratio: 34.360

PEG Ratio: 1.230

Split: On 2/27/2006 CELG split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 25.00 %

EPS Growth in Last Year: 47.06 %

Sales Growth in Last Quarter: 10.57 %

Sales Growth in Last Quarter: 17.33 %

Financials

Qtr Book Value: $6.14

Cash Flow/Share: $32.52

Change in Payout Ratio: 0.000

Price/Sales: 9.860